Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy Report Summary

Efficacy of stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy Report Summary

Author or authors of report : Alper Dai, Osman Baspinar, Ahmet Yeşilyurt, Eda Sun, Çiğdem İnci Aydemir, Olga Nehir Öztel, Davut Unsal Capkan, Ferda Pinarli, Abdullah Agar, Erdal Karaöz
Date of report : 2018-10-26
Muscular Dystrophy
 

Major Points and Findings:

  1. Purpose: The study aimed to investigate the effects of allogeneic Wharton jelly-derived mesenchymal stem cells (WJ-MSCs) therapy in children with Duchenne muscular dystrophy (DMD). DMD is an X-linked recessive pediatric disorder leading to progressive muscle degeneration. The study explored the potential of cell-based therapies to promote muscle regeneration.
  2. Patients and Methods: The study involved nine male patients, four of whom were ambulatory and five nonambulatory. These patients underwent various tests, including gene expression and immunohistochemical analysis for dystrophin gene expression. The fluorescent in situ hybridization method was employed to detect chimerism and donor–recipient compatibility. All patients were treated with a specific dose of allogeneic WJ-MSCs via intra-arterial and intramuscular administration. The patients were then monitored using respiratory capacity tests, cardiac measurements, and muscle strength tests.
  3. Results:
    • The vastus intermedius muscle was observed in one patient using MRI.
    • Chimerism was detected by fluorescent in situ hybridization, and there was a mean gene expression increase of 3.3-fold.
    • An improvement in muscle strength measurements and pulmonary function tests was noted.
    • Two of the nine patients showed a positive panel reactive antigen result.
  4. Conclusion: The procedures were well-tolerated, with no complications related to the application observed. The primary goal was to assess the effects of allogeneic mesenchymal stem cell therapy and determine its safety and suitability as a potential treatment for this otherwise untreatable disorder.
  5. Background Information: DMD results from the absence of dystrophin, leading to progressive muscle degeneration. The clinical findings in DMD patients show a progressive loss of functional abilities, including movement, breathing, and blood circulation. Traditional treatments for DMD, such as corticosteroids, have limited efficacy and come with side effects. Cell-based therapies, especially those using stem cells, have emerged as promising treatments due to their regenerative and immunomodulatory abilities.